Skip to main content
. 2018 Jul 24;109(9):2841–2851. doi: 10.1111/cas.13712

Figure 4.

Figure 4

Complementarity of periostin (POSTN) and carbohydrate antigen 242 (CA242) for CA19.9 in the diagnosis of pancreatic ductal adenocarcinoma (PDAC). Receiver operating characteristic curves of CA19.9, CA19.9 + POSTN, CA19.9 + CA242, POSTN + CA242, and CA19.9 + POSTN + CA242 in the training and validation cohorts. To distinguish PDAC early stage from healthy controls (A, B), all PDAC from benign disease (C, D), and PDAC early stage from benign disease (E, F), in the training and validation cohorts, respectively